Logo image of IPA

IMMUNOPRECISE ANTIBODIES LTD (IPA) Stock Fundamental Analysis

NASDAQ:IPA - Nasdaq - CA45257F2008 - Common Stock - Currency: USD

0.3861  -0.02 (-4.22%)

After market: 0.3859 0 (-0.05%)

Fundamental Rating

2

Overall IPA gets a fundamental rating of 2 out of 10. We evaluated IPA against 57 industry peers in the Life Sciences Tools & Services industry. IPA has a bad profitability rating. Also its financial health evaluation is rather negative. IPA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IPA had negative earnings in the past year.
IPA had a negative operating cash flow in the past year.
In the past 5 years IPA always reported negative net income.
IPA had a negative operating cash flow in each of the past 5 years.
IPA Yearly Net Income VS EBIT VS OCF VS FCFIPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

IPA's Return On Assets of -45.92% is on the low side compared to the rest of the industry. IPA is outperformed by 85.96% of its industry peers.
The Return On Equity of IPA (-84.27%) is worse than 77.19% of its industry peers.
Industry RankSector Rank
ROA -45.92%
ROE -84.27%
ROIC N/A
ROA(3y)-32.43%
ROA(5y)-25.28%
ROE(3y)-49.42%
ROE(5y)-38.79%
ROIC(3y)N/A
ROIC(5y)N/A
IPA Yearly ROA, ROE, ROICIPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

IPA has a Gross Margin of 50.27%. This is comparable to the rest of the industry: IPA outperforms 57.89% of its industry peers.
IPA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for IPA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.62%
GM growth 5Y0.29%
IPA Yearly Profit, Operating, Gross MarginsIPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

1

2. Health

2.1 Basic Checks

IPA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IPA has more shares outstanding than it did 1 year ago.
IPA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, IPA has a worse debt to assets ratio.
IPA Yearly Shares OutstandingIPA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IPA Yearly Total Debt VS Total AssetsIPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

IPA has an Altman-Z score of -2.27. This is a bad value and indicates that IPA is not financially healthy and even has some risk of bankruptcy.
IPA has a Altman-Z score of -2.27. This is in the lower half of the industry: IPA underperforms 78.95% of its industry peers.
A Debt/Equity ratio of 0.45 indicates that IPA is not too dependend on debt financing.
IPA has a Debt to Equity ratio (0.45) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z -2.27
ROIC/WACCN/A
WACC9.86%
IPA Yearly LT Debt VS Equity VS FCFIPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

IPA has a Current Ratio of 1.01. This is a normal value and indicates that IPA is financially healthy and should not expect problems in meeting its short term obligations.
IPA's Current ratio of 1.01 is on the low side compared to the rest of the industry. IPA is outperformed by 85.96% of its industry peers.
IPA has a Quick Ratio of 1.01. This is a bad value and indicates that IPA is not financially healthy enough and could expect problems in meeting its short term obligations.
IPA's Quick ratio of 0.85 is on the low side compared to the rest of the industry. IPA is outperformed by 84.21% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 0.85
IPA Yearly Current Assets VS Current LiabilitesIPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

IPA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.13%, which is quite impressive.
Looking at the last year, IPA shows a small growth in Revenue. The Revenue has grown by 6.36% in the last year.
IPA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.55% yearly.
EPS 1Y (TTM)28.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)6.36%
Revenue growth 3Y11.03%
Revenue growth 5Y17.55%
Sales Q2Q%-0.41%

3.2 Future

The Earnings Per Share is expected to grow by 28.10% on average over the next years. This is a very strong growth
IPA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.57% yearly.
EPS Next Y14.37%
EPS Next 2Y26.68%
EPS Next 3Y28.26%
EPS Next 5Y28.1%
Revenue Next Year0.58%
Revenue Next 2Y5.13%
Revenue Next 3Y14.4%
Revenue Next 5Y15.57%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
IPA Yearly Revenue VS EstimatesIPA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M
IPA Yearly EPS VS EstimatesIPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPA. In the last year negative earnings were reported.
Also next year IPA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPA Price Earnings VS Forward Price EarningsIPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPA Per share dataIPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as IPA's earnings are expected to grow with 28.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.68%
EPS Next 3Y28.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOPRECISE ANTIBODIES LTD

NASDAQ:IPA (2/21/2025, 8:00:01 PM)

After market: 0.3859 0 (-0.05%)

0.3861

-0.02 (-4.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)12-10 2024-12-10/bmo
Earnings (Next)03-12 2025-03-12/bmo
Inst Owners4.17%
Inst Owner Change0.52%
Ins Owners1.26%
Ins Owner ChangeN/A
Market Cap17.67M
Analysts80
Price Target5.1 (1220.9%)
Short Float %0.83%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.41%
Min EPS beat(2)-35.01%
Max EPS beat(2)6.2%
EPS beat(4)2
Avg EPS beat(4)-8.11%
Min EPS beat(4)-35.01%
Max EPS beat(4)6.2%
EPS beat(8)5
Avg EPS beat(8)2.46%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-14.31%
Min Revenue beat(2)-22.81%
Max Revenue beat(2)-5.81%
Revenue beat(4)1
Avg Revenue beat(4)-7.3%
Min Revenue beat(4)-22.81%
Max Revenue beat(4)1.5%
Revenue beat(8)3
Avg Revenue beat(8)-3.56%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.67%
EPS NQ rev (1m)30.43%
EPS NQ rev (3m)0%
EPS NY rev (1m)14.29%
EPS NY rev (3m)16.13%
Revenue NQ rev (1m)-1.83%
Revenue NQ rev (3m)-12.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.04
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 14.34
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0.37
BVpS0.5
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.92%
ROE -84.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.27%
FCFM N/A
ROA(3y)-32.43%
ROA(5y)-25.28%
ROE(3y)-49.42%
ROE(5y)-38.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.62%
GM growth 5Y0.29%
F-Score2
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.64%
Cap/Sales 5.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 0.85
Altman-Z -2.27
F-Score2
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)25%
Cap/Depr(5y)25.27%
Cap/Sales(3y)6.15%
Cap/Sales(5y)5.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y14.37%
EPS Next 2Y26.68%
EPS Next 3Y28.26%
EPS Next 5Y28.1%
Revenue 1Y (TTM)6.36%
Revenue growth 3Y11.03%
Revenue growth 5Y17.55%
Sales Q2Q%-0.41%
Revenue Next Year0.58%
Revenue Next 2Y5.13%
Revenue Next 3Y14.4%
Revenue Next 5Y15.57%
EBIT growth 1Y18.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y61.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.87%
OCF growth 3YN/A
OCF growth 5YN/A